medical marijuana (CBD oil)
If you have a chronic illness, it’s very likely you’ve investigated every treatment possible. Medical marjiuana may have crossed your mind, but up until now it hasn’t been easily available to you. With medicinal marjiuana globally acknowledged as an effective treatment for chronic pain and several other specific conditions, the Therapeutic Goods Authority is now authorising the legal prescribing of medicinal cannabis in WA. This has led to the use of medical marijuana slowly becoming more accessible (and more widely accepted) within our community.
Our own Dr Aparna Hegde is now approved as an Authorised Prescriber for Azure Medical and will exclusively manage all appointment screening, consultations, approvals and prescriptions.
If you suffer from a condition where there is evidence that medical marijuana may be effective and you have already tried conventional treatments you may be a candidate.
Conditions that may be eligible include:
- Chronic pain
- Cancer pain
- Spinal pain
- Eating disorders
- Sleep disorders
- Inflammatory Bowel Disease
- Autism Spectrum Disorder
- Movement disorders
- Mood disorders.
It is important to acknowledge that the effectiveness of medical marijuana differs from person to person. This is not a ‘one size fits all’ treatment so each plan must cater to the individual with care and consideration.
Currently Dr. Hegde is approved to prescribe Schedule 4 products, consisting of LGP, Tilray and Satipharm in the form of CBD oil; and is in the process of approval for Schedule 8 products.
Schedule 4 products contain only cannabidiol (CBD) and do not contain any tetrahydrocannabinol (THC), the psychoactive component of cannabis, which means there are no cognitive effects (effects on the brain that can cause sedation, inco-ordination, etc) associated with CBD. Therefore under this treatment it is still safe to drive and perform other activities.
Schedule 8 products contain both THC and CBD in different concentrations. This THC component is very useful in managing chronic pain, insomnia, anxiety and palliative care patients however side effects may be present, and will need to be monitored.